- POAI
is leveraging the potential of AI and smart tumor profiling to predict
tumor drug response
- TumorGenesis
is developing innovative techniques for growing tumors in laboratory
settings
- Helomics
uses vital information from patients’ own living tumors to assist
oncologists in selecting the most effective treatments
Predictive
Oncology Inc. (NASDAQ: POAI) is harnessing the power of artificial
intelligence (AI) and rich information from patients’ own tumors to improve
outcomes for cancer patients. Predictive Oncology applies its proprietary smart
tumor profiling and AI platform to extensive genomic and biomarker patient
datasets in order to predict tumor drug response and improve clinical outcomes
for cancer patients.
Last year, POAI, then known as Precision Therapeutics,
formed TumorGenesis to focus on innovative ways to create improved patient
derived (PDx) tumor models. Currently, TumorGenesis is working on developing
new techniques for growing tumors in the lab to generate more relevant models
of the tumors that can be used to test drugs for personalized therapy or aid in
development of new medications.
The approach is designed to grow tumors in the lab by
providing an environment that closely mimics the human body, through the use of
chemistry, biology, mechanics and cell nutrients. In addition to this exclusive
technology being quicker and more affordable than existing PDx animal models,
researchers anticipate that the approach will better replicate the
characteristics of tumors. Initially, the company plans to develop PDx models
for multiple myeloma, triple-negative breast cancer and ovarian cancer, but
Predictive is expecting the technology to ultimately benefit oncologists who
are investigating other cancer areas as well, including liver, pancreatic, lung
and colon.
To validate these new tumor models, TumorGenesis is working
closely with Predictive’s Helomics team and is also actively looking for
external partners that could potentially benefit from these innovative
technologies and advance research.
Helomics is dedicated to improving the standard of care for
cancer patients by using vital information provided by patients’ own living
tumors to assist oncologists in selecting the most effective treatments.
Helomics uses its exclusive tumor drug-response profiling platform, together
with the latest next-generation sequencing (NGS)-based genomic profiling and
its vast knowledgebase of 150,000 tumors, to provide additional context to
create a valuable predictive tool for clinicians and researchers. This approach
is rooted in the company’s belief that capturing this invaluable
patient-specific information in conjunction with such a huge historical
database provides a more functional approach to precision medicine than relying
on genomics alone.
In a page straight out of Sun Tzu’s The Art of War,
Predictive Oncology is helping oncologists and researchers “know the enemy” by
harnessing rich information from patient tumors using artificial intelligence
to build predictive models of tumor drug response. Predictive Oncology is
working with the pharmaceutical, diagnostic and biotech industries to use these
models to both improve the development of new drugs and help clinicians
individualize therapy. For investors, Predictive Oncology offers the possibility
for significant ROI, as it has already amassed (through its acquisition of
Helomics) a huge cancer dataset that can be mined to provide valuable insights
to improve treatment.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
